|
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced the company presenting modeling data evaluating the simulated benefit and burden of established CRC screening strategies, including the Cologuard Plus test during the American College of Gastroenterology (ACG) Annual Meeting. ACG is taking place from October 25 to 30, 2024, in Philadelphia, Pennsylvania.
Exact Sciences will also present new data on improving adherence to help close the gap in CRC screening.
“Exact Sciences will share new modeling data which demonstrates the Cologuard Plus test as an efficient CRC screening strategy across modeled age ranges and screening intervals, given its high sensitivity and specificity for both cancer and precancer,” said Paul Limburg, chief medical officer for Screening, Exact Sciences. “The data demonstrate our commitment to continuous improvement and innovation to deliver best in class, patient-centric cancer screening and diagnostic solutions.”
Researchers used a validated simulation model to assess the benefit to burden ratio of the Cologuard Plus test and other established and emerging CRC screening options. Benefit was defined as life-years gained and burden as the lifetime number of colonoscopies.
The efficient frontier abstract summary and presentation details are as follows:
Next Generation mt-sDNA Has the Best Balance Between Benefit and Burden of Age- and Interval-Recommended CRC Screening Among Stool- and Blood-Based Tests (P2119).
The next-generation mt-sDNA (ng-mt-sDNA) test was the only efficient non-invasive modality for screening over the guideline-recommended age interval of 45-75 years; Blood-based screening strategies were not efficient or near-efficient at any screening interval or age-range.
The seven remaining abstracts share patient-centric research on improving CRC screening adherence rates, particularly in underserved populations. With industry-leading patient navigation and personalized outreach, these strategies directly impact millions of lives. When modeled against the US general screening population, widespread implementation of the reported strategies could drive as much as a 10% reduction in the CRC screening gap.
|